Two Hands Corp — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Two Hands Corp filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $709.5K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $783.5K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $731.3K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $930.1K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $159.0K | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $390.4K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $43.5K | Apr 1, 2019 |
| FY2014 | Dec 31, 2014 | $79.1K | Apr 15, 2015 |
| FY2013 | Dec 31, 2013 | $21.0K | Apr 15, 2014 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $43.5K | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $133.6K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $35.9K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $79.1K | Mar 29, 2016 |
| FY2011 | Dec 31, 2011 | $0 | Apr 2, 2012 |
| FY2011 | Dec 31, 2010 | $21.0K | Apr 2, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $51.8K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $62.1K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $49.2K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $97.3K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $20.6K | Mar 31, 2022 |
| FY2017 | Dec 31, 2017 | $43.5K | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $90.7K | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $35.9K | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $79.1K | Mar 29, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($484.9K) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($2.43M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($8.16M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($21.69M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($16.34M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($7.67M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($5.68M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($8.10M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($877.9K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($769.9K) | Mar 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.06M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($1.17M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($1.28M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($17.80M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.17M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($5.50M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.70M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($4.50M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($849.1K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($675.1K) | Mar 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $0 | Apr 3, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | $361.2K | Mar 27, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($807.9K) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($250.5K) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($451.9K) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($840.7K) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($557.9K) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($314.4K) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($472.1K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($235.3K) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($161.4K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($58.8K) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $10.7K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.4K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $2.2K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.6K | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $1.7K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $2.0K | Apr 1, 2019 |
| FY2014 | Dec 31, 2013 | $693 | Apr 15, 2015 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $318.6K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $97.7K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $194.6K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $230.2K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.65M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $967.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.77M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $429.8K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $20.5K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $11.5K | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26M | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $3.67M | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $2.92M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.92M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.31M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $1.66M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.59M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $740.2K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $717.2K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $294.1K | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.95M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($3.57M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2023 | ($2.80M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2022 | ($4.64M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2021 | ($3.74M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | ($2.78M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2019 | ($1.37M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($310.4K) | Mar 29, 2021 |
| FY2019 | Dec 31, 2017 | ($696.7K) | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | ($282.6K) | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($95.01M) | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | ($94.52M) | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | ($92.09M) | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | ($83.92M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($62.23M) | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | ($45.89M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($38.23M) | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | ($32.55M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($24.45M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($23.58M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $227.6K | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | $1.7K | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | $24.4K | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | $17.1K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $533.3K | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | $21.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $293 | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | $2.7K | Mar 27, 2020 |
| FY2019 | Dec 31, 2017 | $18.8K | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | $1.3K | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | (229) | Apr 1, 2024 |
| FY2017 | Dec 31, 2017 | 0 | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | (1) | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Mar 29, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Apr 15, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Apr 15, 2014 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | (229) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6.50B | Apr 10, 2026 |
| FY2025 | Dec 31, 2024 | 5.47B | Apr 10, 2026 |
| FY2024 | Dec 31, 2023 | 42.09M | Apr 14, 2025 |
| FY2023 | Dec 31, 2022 | 137,403 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 6.00M | Apr 3, 2023 |
| FY2021 | Dec 31, 2020 | 695.58M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 6.27M | Mar 29, 2021 |
| FY2019 | Dec 31, 2018 | 152,199 | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | 812,435 | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | 812,435 | Apr 1, 2019 |